Venlafaxine
- 1 February 1995
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 49 (2) , 280-294
- https://doi.org/10.2165/00003495-199549020-00010
Abstract
Venlafaxine is a phenylethylamine derivative which facilitates neurotransmission in the brain by blocking presynaptic reuptake of serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine). Clinical data from patients with major depression are consistent with the favourable efficacy and tolerability profile of venlafaxine predicted by pharmacodynamic studies.Keywords
This publication has 32 references indexed in Scilit:
- Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour MonitoringPharmacopsychiatry, 1996
- A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholiaInternational Clinical Psychopharmacology, 1994
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sciences, 1993
- Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigmNeuropharmacology, 1993
- Metabolic disposition of14C-venlafaxine in mouse, rat, dog, rhesus monkey and manXenobiotica, 1993
- Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjectsInternational Clinical Psychopharmacology, 1993
- Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl MetaboliteThe Journal of Clinical Pharmacology, 1992
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- The Epidemiology of Depression in Medical CareThe International Journal of Psychiatry in Medicine, 1988
- Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitorsPsychological Medicine, 1983